Tag Archives: patients

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

Todd

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original intent, leading to evidence of abuse and potentially harmful consequences for patients. “The original intent of 340B was to support the most vulnerable patients; clearly that is not the focus for many of the participants in the program now,” said Todd. Todd pointed to three primary reasons the program needs more oversight: Exponential growth, significant violations revealed in audits, and Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

AIR 340B: New Analysis Shows Most 340B Hospitals Provide Little Charity Care

95468934

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a new report, showing that a substantial portion of hospitals enrolled in the 340B drug discount program provide only the barest amount of charity care, and as such they are not fulfilling Congress’ expectations about the program. Congress created the program in 1992 to help uninsured indigent patients gain better access to prescription medicines. The original intention of the program was to provide Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , ,

Rare Disease Day 2014: Joining Together for Better Care

Hans Schikan of Prosensa

There are more than 6,000 different rare diseases affecting over 60 million people across Europe and North America, alone, and millions more throughout the world. Most of these diseases are genetic, serious, chronic and debilitating. Each disease is different, but they affect people in similar ways. Joining together can help patients and their families find common solutions for care and remind them they are not alone. As the world marks Rare Disease Day on February Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , , , , , , , , , ,

FDA Week: For Biologics, A Name Isn’t Just A Name (Jim Greenwood op-ed)

Jim Greenwood

What is in a name? Names help make medicinal products more easily distinguishable by doctors, pharmacists and patients. When you are talking about biologics, complex medicines that are manufactured using living organisms, and biosimilars, medicines that are similar to, but not the same as, innovator biologics, naming is a significant consideration. As a pathway for biosimilars approval is implemented, a clear priority should be to craft a naming convention that both contributes to patient safety Read More >

Jim's Corner  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Putting Patients First: Paving a Path to Useful CER

NPC_emailbanner_web

Comparative effectiveness research (CER) has the potential to improve health outcomes by helping people make better-informed decisions. But how do we know that CER will generate information that is useful? On September 30, in Washington, DC, you can be part of a conversation featuring a broad range of health care stakeholders—patients, providers, policymakers, payers, researchers, and those who fund research–by participating in an effort led by the National Health Council to create a framework to Read More >

Events, Health  |  Leave a comment  |  Email This Post
Tags: , , , ,